Search - tctmd.com

Displaying 561 - 580 of 1053

Sort: Relevancy | Date

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

News Conference News ACC 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

March 22, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

News Conference News ACC 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

March 10, 2017

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

News Daily News

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

February 24, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

News Daily News

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

Yael L. Maxwell

February 13, 2017

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

TCTMD’s Top 10 Most Popular Stories for January 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2017

February 01, 2017

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

News Daily News

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

January 30, 2017

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

News Daily News

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

Michael O'Riordan

January 26, 2017

News Daily News

Even With Early Invasive Strategy in NSTE ACS, Women Face Poorer Outcomes Than Men

January 24, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.